ZWJ Investment Counsel Inc. lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 318,705 shares of the biopharmaceutical company’s stock after selling 3,990 shares during the period. Gilead Sciences comprises about 1.8% of ZWJ Investment Counsel Inc.’s portfolio, making the stock its 18th biggest position. ZWJ Investment Counsel Inc.’s holdings in Gilead Sciences were worth $22,558,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Nippon Life Insurance Co. grew its position in shares of Gilead Sciences by 22.8% in the 2nd quarter. Nippon Life Insurance Co. now owns 81,108 shares of the biopharmaceutical company’s stock valued at $5,741,000 after buying an additional 15,063 shares during the last quarter. Pegasus Partners Ltd. grew its position in shares of Gilead Sciences by 13.2% in the 2nd quarter. Pegasus Partners Ltd. now owns 21,196 shares of the biopharmaceutical company’s stock valued at $1,500,000 after buying an additional 2,472 shares during the last quarter. Nikko Asset Management Americas Inc. grew its position in shares of Gilead Sciences by 261.9% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 35,100 shares of the biopharmaceutical company’s stock valued at $2,484,000 after buying an additional 25,400 shares during the last quarter. Penobscot Investment Management Company Inc. grew its position in shares of Gilead Sciences by 10.8% in the 2nd quarter. Penobscot Investment Management Company Inc. now owns 7,210 shares of the biopharmaceutical company’s stock valued at $510,000 after buying an additional 700 shares during the last quarter. Finally, Windsor Financial Group LLC boosted its position in shares of Gilead Sciences by 8.6% during the 2nd quarter. Windsor Financial Group LLC now owns 9,769 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 772 shares in the last quarter. Hedge funds and other institutional investors own 73.97% of the company’s stock.

In other news, EVP Gregg H. Alton sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total value of $3,950,000.00. Following the completion of the sale, the executive vice president now directly owns 113,237 shares in the company, valued at approximately $8,945,723. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at $242,749,648.34. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 446,819 shares of company stock valued at $36,338,919. Company insiders own 1.30% of the company’s stock.

WARNING: “ZWJ Investment Counsel Inc. Has $22.56 Million Holdings in Gilead Sciences, Inc. (GILD)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/zwj-investment-counsel-inc-has-22-56-million-holdings-in-gilead-sciences-inc-gild/1646908.html.

Several equities research analysts recently commented on the company. BMO Capital Markets restated a “hold” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Friday. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday. Leerink Swann upped their target price on Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a research report on Thursday. William Blair restated a “buy” rating on shares of Gilead Sciences in a research report on Thursday. Finally, Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the company a “buy” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $85.64.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 81.21 on Friday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The stock has a market capitalization of $106.05 billion, a P/E ratio of 8.82 and a beta of 1.14. The firm has a 50-day moving average price of $82.63 and a 200-day moving average price of $72.65.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the previous year, the business earned $3.08 EPS. On average, analysts predict that Gilead Sciences, Inc. will post $8.74 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were paid a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.56%. Gilead Sciences’s dividend payout ratio is presently 22.58%.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.